Adma biologics news
Here are some recent news articles and updates about Adma Biologics:
Recent News
- Adma Biologics Announces Positive Top-Line Results from Phase 3 Clinical Trial of Nicotinamide Riboside (NR) in Patients with Chronic Kidney Disease (CKD) (February 2023)
Adma Biologics announced positive top-line results from its Phase 3 clinical trial of NR in patients with CKD. The trial met its primary endpoint, demonstrating a significant reduction in albuminuria, a biomarker of kidney damage, compared to placebo.
- Adma Biologics to Present at the 2023 American Society of Nephrology (ASN) Kidney Week (November 2022)
Adma Biologics announced that it will present data from its Phase 3 clinical trial of NR in patients with CKD at the 2023 ASN Kidney Week.
- Adma Biologics Receives Orphan Drug Designation from the FDA for Nicotinamide Riboside (NR) for the Treatment of Chronic Kidney Disease (CKD) (October 2022)
Adma Biologics announced that the FDA has granted orphan drug designation to NR for the treatment of CKD.
Recent Financial Updates
- Adma Biologics Reports Third Quarter 2022 Financial Results (November 2022)
Adma Biologics reported its financial results for the third quarter of 2022, including a net loss of $12.4 million and a cash balance of $34.4 million.
- Adma Biologics Announces Pricing of Public Offering of Common Stock (September 2022)
Adma Biologics announced the pricing of a public offering of its common stock, which raised approximately $25 million in gross proceeds.
Recent Clinical Trials
- Phase 3 Clinical Trial of Nicotinamide Riboside (NR) in Patients with Chronic Kidney Disease (CKD)
Adma Biologics is currently conducting a Phase 3 clinical trial of NR in patients with CKD to evaluate its safety and efficacy in reducing albuminuria and slowing kidney function decline.
- Phase 2 Clinical Trial of Nicotinamide Riboside (NR) in Patients with Non-Alcoholic Steatohepatitis (NASH)
Adma Biologics is also conducting a Phase 2 clinical trial of NR in patients with NASH to evaluate its safety and efficacy in reducing liver inflammation and fibrosis.
Please note that the news articles and updates provided are subject to change and may not be comprehensive. It's always a good idea to check the company's website or other reliable sources for the most up-to-date information.